1. Discovery of 6,7-Dihydropyrazolo[1,5- a ]pyrazin-4(5 H )-one Derivatives as mGluR 2 Negative Allosteric Modulators with In Vivo Activity in a Rodent's Model of Cognition.
- Author
-
Alonso de Diego SA, Linares ML, García Molina A, de Lucas AI, Del Cerro A, Alonso JM, Ver Donck L, Cid JM, Trabanco AA, and Van Gool M
- Subjects
- Animals, Allosteric Regulation drug effects, Structure-Activity Relationship, Rats, Humans, Pyrazines pharmacology, Pyrazines chemistry, Pyrazines pharmacokinetics, Pyrazines chemical synthesis, Male, Maze Learning drug effects, Mice, Drug Discovery, Receptors, Metabotropic Glutamate metabolism, Cognition drug effects, Pyrazoles pharmacology, Pyrazoles chemistry, Pyrazoles chemical synthesis, Pyrazoles pharmacokinetics
- Abstract
Allosteric modulators of the metabotropic group II receptors, mGluR
2 and mGluR3 , have been widely explored due to their ability to modulate cognitive and neurological functions in mood disorders, although none have been approved yet. In our search for new and selective mGluR2 negative allosteric modulators (NAMs), series of 6,7-dihydropyrazolo[1,5- a ]pyrazin-4(5 H )-one derivatives were identified from our published series of 1,3,5-trisubstituted pyrazoles. SAR evolution of the initial hit resulted in 100-fold improvement in the mGluR2 NAM potency and subsequent selection of compound 11 based on its overall profile, including selectivity and ADMET properties. Further pharmacokinetic-pharmacodynamic (PK-PD) relationship built showed that compound 11 occupied the mGluR2 receptor in a dose-dependent manner. Additionally, the compound revealed in vivo activity in V-maze as a model of cognition from a dose of 0.32 mg/kg. Compound 11 was selected to be evaluated further.- Published
- 2024
- Full Text
- View/download PDF